Efficacy and Safety of Anlotinib, Irinotecan and Temozolomide in the Treatment of Refractory or Recurrent Neuroblastoma in Children: an Open, Single Arm, Single Center, Phase II Clinical Study

NCT04842526 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

27

Enrollment

OTHER

Sponsor class

Conditions

Refractory or Recurrent Neuroblastoma in Children

Interventions

DRUG: Anlotinib and irinotecan combined with temozolomide

Sponsor

Tianjin Medical University Cancer Institute and Hospital

Collaborators

[object Object]